CoChat

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Background We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. Despite a lack of objective responses to the combination, patients who received a higher dose of TGFβ blocking antibody fresolimumab had a better overall survival when compared to those assigned to lower dose (hazard ratio of 2.73, p = 0.039). They also demonstrated an improved peripheral blood mononuclear cell (PBMC) counts and increase in the CD8 central memory pool. We performed additional analysis on residual PBMC using single cell network profiling (SCNP). Methods The original trial randomized metastatic breast cancer patients to either 1 or 10 mg/kg of fresolimumab, every 3 weeks for 5 cycles, combined with radiotherapy to a metastatic site at week 1 and 7 (22.5 Gy given in 3 doses of 7.5 Gy). Trial immune monitoring results were previously reported. In 15 patients with available residual blood samples, additional functional studies were performed, and compared with data obtained in parallel from seven healthy female donors (HD): SCNP was applied to analyze T cell receptor (TCR) modulated signaling via CD3 and CD28 crosslinking and measurement of evoked phosphorylation of AKT and ERK in CD4 and CD8 T cell subsets defined by PD-1 expression. Results At baseline, a significantly higher level of expression (p < 0.05) of PD-L1 was identified in patient monocytes compared to HD. TCR modulation revealed dysfunction of circulating T-cells in patient baseline samples as compared to HD, and this was more pronounced in PD-1+ cells. Treatment with radiotherapy and fresolimumab did not resolve this dyfunctional signaling. However, in vitro PD-1 blockade enhanced TCR signaling in patient PD-1+ T cells and not in PD-1- T cells or in PD-1+ T cells from HD. Conclusions Functional T cell analysis suggests that baseline T cell functionality is hampered in metastatic breast cancer patients, at least in part mediated by the PD-1 signaling pathway. These preliminary data support the rationale for investigating the possible beneficial effects of adding PD-1 blockade to improve responses to TGFβ blockade and radiotherapy. Trial registration NCT01401062.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0633-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Increased PD-L1 expression and decreased TCR signaling in breast cancer patients PBMC compared to HD. a-b Samples were analyzed at baseline for expression of immunomodulatory receptors. a Significantly higher levels of PD-L1 on monocytes of breast cancer patients compared to healthy donors (HD). b Higher levels of PD-1 on CD4 T cells of breast cancer patients compared to HD. c, d TCR modulated signaling in CD8 T cells from HD and patients at baseline and during treatment, as measured by phosphorylation of AKT. c Analysis of all available samples from patients treated in arm 1 (1 mg/kg of fresolimumab) and arm 2 (10 mg/kg of fresolimumab) shows overall reduced TCR signaling in CD8 T cells of patients compared to HD. Each dot represents one individual. Unpaired t test, two-tailed, *p < 0.05, **P < 0.005. (D) pAKT values were plotted overtime for 7 patients with baseline and at least one post-treatment sample measurements
Fig. 1 Increased PD-L1 expression and decreased TCR signaling in breast cancer patients PBMC compared to HD. a-b Samples were analyzed at baseline for expression of immunomodulatory receptors. a Significantly higher levels of PD-L1 on monocytes of breast cancer patients compared to healthy donors (HD). b Higher levels of PD-1 on CD4 T cells of breast cancer patients compared to HD. c, d TCR modulated signaling in CD8 T cells from HD and patients at baseline and during treatment, as measured by phosphorylation of AKT. c Analysis of all available samples from patients treated in arm 1 (1 mg/kg of fresolimumab) and arm 2 (10 mg/kg of fresolimumab) shows overall reduced TCR signaling in CD8 T cells of patients compared to HD. Each dot represents one individual. Unpaired t test, two-tailed, *p < 0.05, **P < 0.005. (D) pAKT values were plotted overtime for 7 patients with baseline and at least one post-treatment sample measurementsCC BY · PubMed Central
Fig. 2 PD-1+ CD4 and CD8 T cells show decreased TCR signaling compared to PD-1- T cells. a, b The response to TCR stimulation was measured using p-AKT and p-ERK as a readout. PD1+ T cells from both HD and patients collected at baseline show significantly reduced TCR modulated signaling compared to PD1− T cells, as measured by phosphorylation of AKT (a) and ERK (b). Significantly reduced TCR modulated AKT phosphorylation is also evident in PD1− T cells from patients compared to HD. Each dot represents one individual and data is represented as Log2Fold value. A log2Fold value of 1 implies a 2-fold change in Equivalent Number of Reference Fluorophores (ERFs) intensity whereas a value close to 2 implies a 4-fold change. *p < 0.05, **P < 0.005, ***P < 0005
Fig. 2 PD-1+ CD4 and CD8 T cells show decreased TCR signaling compared to PD-1- T cells. a, b The response to TCR stimulation was measured using p-AKT and p-ERK as a readout. PD1+ T cells from both HD and patients collected at baseline show significantly reduced TCR modulated signaling compared to PD1− T cells, as measured by phosphorylation of AKT (a) and ERK (b). Significantly reduced TCR modulated AKT phosphorylation is also evident in PD1− T cells from patients compared to HD. Each dot represents one individual and data is represented as Log2Fold value. A log2Fold value of 1 implies a 2-fold change in Equivalent Number of Reference Fluorophores (ERFs) intensity whereas a value close to 2 implies a 4-fold change. *p < 0.05, **P < 0.005, ***P < 0005CC BY · PubMed Central
Fig. 3 Anti-PD-1 antibody restores TCR signaling in PD-1+ CD4 T cells from breast cancer patients. a-d PBMC from HD (Left panels) and patients (Right panels) were stimulated with anti-CD3 and anti-CD28 in the presence of anti-PD-1 antibody pembrolizumab (anti-PD-1) or isotype control antibody (Isotype). Graphs show the results for PD1+ T cells, as measured by phosphorylation of AKT (a) and ERK (b). Stimulation in the presence of anti-PD-1 did not significantly increase the response of PD1+ CD4 T cells from HD, but increased the response of PD-1+ CD4 T cells from patients, achieving significance as measured by AKT phosphorylation and showing a trend to significance, as measured by ERK phosphorylation. Stimulation in the presence of anti-PD-1 did not significantly increase the response of PD1− CD4 T cells from HD and patients as measured by phosphorylation of AKT (c) or ERK (d). Each line corresponds to one individual. T test, two-tailed, *p < 0.05, **P < 0.005
Fig. 3 Anti-PD-1 antibody restores TCR signaling in PD-1+ CD4 T cells from breast cancer patients. a-d PBMC from HD (Left panels) and patients (Right panels) were stimulated with anti-CD3 and anti-CD28 in the presence of anti-PD-1 antibody pembrolizumab (anti-PD-1) or isotype control antibody (Isotype). Graphs show the results for PD1+ T cells, as measured by phosphorylation of AKT (a) and ERK (b). Stimulation in the presence of anti-PD-1 did not significantly increase the response of PD1+ CD4 T cells from HD, but increased the response of PD-1+ CD4 T cells from patients, achieving significance as measured by AKT phosphorylation and showing a trend to significance, as measured by ERK phosphorylation. Stimulation in the presence of anti-PD-1 did not significantly increase the response of PD1− CD4 T cells from HD and patients as measured by phosphorylation of AKT (c) or ERK (d). Each line corresponds to one individual. T test, two-tailed, *p < 0.05, **P < 0.005CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 56

Metadata

Authors
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., & Demaria, S.
Affiliations
  • Weill Cornell Medicine (US)
  • Gilead Sciences (United States) (US)
  • Nodality (United States) (US)
  • University of California, Los Angeles (US)
  • New York University (US)
Corresponding author
  • Formenti, Silvia C.
  • Demaria, Sandra
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-07-11
Volume
7
Issue
1
Pages
177-177
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2959936824
Cited by
53
References
23
Citations by year
2026: 4 · 2025: 7 · 2024: 9 · 2023: 7 · 2022: 5 · 2021: 13 · 2020: 7 · 2019: 1
FWCI
2.72
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • U.S. Department of Defense (W81XWH-11-1-0530, W81XWH-11-1-0531)
  • Breast Cancer Research Foundation
  • National Cancer Institute (5P30CA16087)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
metastatic breast cancer, T cell dysfunction, TGF-beta blockade, radiotherapy, PD-1 signaling, PD-L1, T cell receptor signaling, anti-PD-1 therapy, immune monitoring
MeSH terms
Adult, Aged, Antineoplastic Agents, Breast Neoplasms, Combined Modality Therapy, Female, Humans, Middle Aged, Receptors, Antigen, T-Cell, CD4-Positive T-Lymphocytes, Transforming Growth Factor beta, CD8-Positive T-Lymphocytes, Young Adult, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. https://app.cochat.ai/papers/10.1186/s40425-019-0633-x
The paper
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., & Demaria, S. (2019). Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0633-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.